We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Clavis Pharma Receives Government Grant to Develop hENT1 Biomarker Assay for Targeted Therapy of AML Patients

News   Jun 01, 2011

 
Clavis Pharma Receives Government Grant to Develop hENT1 Biomarker Assay for Targeted Therapy of AML Patients
 
 
 

RELATED ARTICLES

Diagnosing Lung Cancer With Artificial Intelligence

News

A new study reports that deep learning — a form of artificial intelligence — was able to detect malignant lung nodules on low-dose chest computed tomography scans with a performance meeting or exceeding that of expert radiologists.

READ MORE

Specialized Microscope Scans and Closes Single Blood Vessels

News

If further developed, this specialized microscope could be revolutionary for the treatment of skin cancer, as it enables incredibly precise surgery – all without cutting skin.

READ MORE

“Metabolic Fingerprint” Could Help Treat, Diagnose and Prevent Cervical Cancer

News

Researchers at the University of Arizona have completed the first-of-its-kind study that could aid in the treatment, diagnosis and prevention of cervical cancer by identifying cervicovaginal metabolic signatures, or "fingerprints" that distinguish patients with HPV, pre-cancerous cervical conditions and cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE